A
Anthony T. DiPiazza
Researcher at National Institutes of Health
Publications - 24
Citations - 1928
Anthony T. DiPiazza is an academic researcher from National Institutes of Health. The author has contributed to research in topics: Immune system & Epitope. The author has an hindex of 14, co-authored 23 publications receiving 1006 citations. Previous affiliations of Anthony T. DiPiazza include University of Rochester Medical Center & Vaccine Research Center.
Papers
More filters
Journal ArticleDOI
SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness.
Kizzmekia S. Corbett,Darin K. Edwards,Sarah R. Leist,Olubukola M. Abiona,Seyhan Boyoglu-Barnum,Rebecca A. Gillespie,Sunny Himansu,Alexandra Schäfer,Cynthia T. Ziwawo,Anthony T. DiPiazza,Kenneth H. Dinnon,Sayda Elbashir,Christine A. Shaw,Angela Woods,Ethan J. Fritch,David R. Martinez,Kevin W. Bock,Mahnaz Minai,Bianca M. Nagata,Geoffrey B. Hutchinson,Kai Wu,Carole Henry,Kapil Bahl,Dario Garcia-Dominguez,Ling Zhi Ma,Isabella Renzi,Wing Pui Kong,Stephen D. Schmidt,Lingshu Wang,Yi Zhang,Emily Phung,Emily Phung,Lauren A. Chang,Rebecca J. Loomis,Nedim Emil Altaras,Elisabeth Narayanan,Mihir Metkar,Vlad Presnyak,Cuiping Liu,Mark K. Louder,Wei Shi,Kwanyee Leung,Eun Sung Yang,Ande West,Kendra Gully,Laura J. Stevens,Nianshuang Wang,Daniel Wrapp,Nicole A. Doria-Rose,Guillaume Stewart-Jones,Hamilton Bennett,Gabriela S. Alvarado,Martha Nason,Tracy J. Ruckwardt,Jason S. McLellan,Mark R. Denison,James D. Chappell,Ian N. Moore,Kaitlyn M. Morabito,John R. Mascola,Ralph S. Baric,Andrea Carfi,Barney S. Graham +62 more
TL;DR: In this article, an mRNA vaccine for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is proposed, which is used to control the CoVID-19 global pandemic.
Journal ArticleDOI
A proof of concept for structure-based vaccine design targeting RSV in humans.
Michelle C. Crank,Tracy J. Ruckwardt,Man Chen,Kaitlyn M. Morabito,Emily Phung,Emily Phung,Pamela Costner,LaSonji A. Holman,Somia P. Hickman,Nina M. Berkowitz,Ingelise J. Gordon,Galina Yamshchikov,Martin R. Gaudinski,Azad Kumar,Lauren A. Chang,Syed M. Moin,Juliane P. Hill,Anthony T. DiPiazza,Richard M. Schwartz,Lisa A. Kueltzo,Jonathan W. Cooper,Peifeng Chen,Judith A Stein,Kevin Carlton,Jason G. D. Gall,Martha Nason,Peter D. Kwong,Grace L. Chen,John R. Mascola,Jason S. McLellan,Julie E. Ledgerwood,Barney S. Graham,Vrc Study Team +32 more
TL;DR: In this article, an iterative round of protein engineering were performed to preserve the prefusion conformation of the respiratory syncytial virus (RSV) fusion (F) glycoprotein, resulting in a stabilized subunit vaccine candidate (DS-Cav1), which showed promising results in mice and macaques.
Journal ArticleDOI
Ultrapotent antibodies against diverse and highly transmissible SARS-CoV-2 variants.
Lingshu Wang,Tongqing Zhou,Yi Zhang,Eun Sung Yang,Chaim A. Schramm,Wei Shi,Amarendra Pegu,Olamide K. Oloniniyi,Amy R. Henry,Samuel Darko,Sandeep Narpala,Christian Hatcher,David R. Martinez,Yaroslav Tsybovsky,Emily Phung,Olubukola M. Abiona,Avan Antia,Evan M. Cale,Lauren A. Chang,Misook Choe,Kizzmekia S. Corbett,Rachel L. Davis,Anthony T. DiPiazza,Ingelise J. Gordon,Sabrina Helmold Hait,Tandile Hermanus,Tandile Hermanus,Prudence Kgagudi,Prudence Kgagudi,Farida Laboune,Kwanyee Leung,Tracy Liu,Rosemarie D. Mason,Alexandra Nazzari,Laura Novik,Sarah O’Connell,Sijy O'Dell,Adam S. Olia,Stephen D. Schmidt,Tyler Stephens,Christopher D. Stringham,Chloe Adrienna Talana,I-Ting Teng,Danielle A. Wagner,Alicia T. Widge,Baoshan Zhang,Mario Roederer,Julie E. Ledgerwood,Tracy J. Ruckwardt,Martin R. Gaudinski,Penny L. Moore,Penny L. Moore,Nicole A. Doria-Rose,Ralph S. Baric,Barney S. Graham,Adrian B. McDermott,Daniel C. Douek,Peter D. Kwong,John R. Mascola,Nancy J. Sullivan,John Misasi +60 more
TL;DR: This paper identified four receptor binding domain-targeting antibodies from three early-outbreak convalescent donors with potent neutralizing activity against 23 variants of SARS-CoV-2 variants of concern (VOCs).
Posted ContentDOI
SARS-CoV-2 mRNA Vaccine Development Enabled by Prototype Pathogen Preparedness
Kizzmekia S. Corbett,Darin K. Edwards,Sarah R. Leist,Olubukola M. Abiona,Seyhan Boyoglu-Barnum,Rebecca A. Gillespie,Sunny Himansu,Alexandra Schäfer,Cynthia T. Ziwawo,Anthony T. DiPiazza,Kenneth H. Dinnon,Sayda Elbashir,Christine A. Shaw,Angela Woods,Ethan J. Fritch,David R. Martinez,Kevin W. Bock,Mahnaz Minai,Bianca M. Nagata,Geoffrey B. Hutchinson,Kapil Bahl,Dario Garcia-Dominguez,LingZhi Ma,Isabella Renzi,Wing-Pui Kong,Stephen D. Schmidt,Lingshu Wang,Yi Zhang,Laura J. Stevens,Emily Phung,Lauren A. Chang,Rebecca J. Loomis,Nedim Emil Altaras,Elisabeth Narayanan,Mihir Metkar,Vladimir Presnyak,Catherine Liu,Mark K. Louder,Wei Shi,Kwanyee Leung,Eun Sung Yang,Ande West,Kendra Gully,Nianshuang Wang,Daniel Wrapp,Nicole A. Doria-Rose,Guillaume Stewart-Jones,Hamilton Bennett,Martha Nason,Tracy J. Ruckwardt,Jason S. McLellan,Mark R. Denison,James D. Chappell,Ian N. Moore,Kaitlyn M. Morabito,John R. Mascola,Ralph S. Baric,Andrea Carfi,Barney S. Graham +58 more
TL;DR: It is shown that mRNA-1273 induces both potent neutralizing antibody and CD8 T cell responses and protects against SARS-CoV-2 infection in lungs and noses of mice without evidence of immunopathology.
Journal ArticleDOI
T cell immunity to SARS-CoV-2 following natural infection and vaccination.
TL;DR: Some of the key mechanisms underlying cell-mediated immunity to respiratory viruses and the current understanding of the functional capacity and role of SARS-CoV-2-specific T cells following natural infection and vaccination are reviewed.